Advertisement

Topics

Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda® (lurasidone HCI) for the Treatment of Bipolar Depression in Children and Adolescents

08:05 EDT 30 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Application seeks to expand LATUDA label to include treatment of depressive symptoms associated with bipolar I disorder in children and adolescents (10 to 17 years of age) – Sunovion Pharmaceuticals Inc. (Sunovi...

Other Sources for this Article

Sunovion Pharmaceuticals Inc.
Kristina Coppola, 508-787-4368
Associate Director, Portfolio Communications
kristina.coppola@sunovion.com

NEXT ARTICLE

More From BioPortfolio on "Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda® (lurasidone HCI) for the Treatment of Bipolar Depression in Children and Adolescents"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Depression
Depression is a serious mental health condition, where sad feelings carry on for weeks or months and interfere with your life. The symptoms include feeling unhappy most of the time (but may feel a little better in the evenings), loosing interest in lif...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...